. 2011 Aug;1812(8):1007–1022. doi: 10.1016/j.bbadis.2011.02.014

Table 2.

Mouse inflammatory models and PPARs. Relevant inflammatory models and the involvement of PPAR subtypes are shown.

Experimental model	PPARα	Ref.	PPARβ/δ	Ref.	PPARγ	Ref.
Experimental autoimmune encephalomyelitis	Ligand treatment: ↓severity ↑IL-4, ↓IFN-γ ↓NO production	[141,142,144]	Ligand treatment: ↓severity	[143]	Ligand treatment: ↓severity ↓IL-12, Th1/Th17 T cells	[106,107,109]
Experimental autoimmune encephalomyelitis	Ligand treatment: ↓severity ↑IL-4, ↓IFN-γ ↓NO production	[141,142,144]	PPARβ/δ^−/− mice: ↑severity ↑IFN-γ, IL-12	[143]	PPARγ^+/− mice: ↑severity	[106,107,109]
Colitis	Ligand treatment: ↓severity ↓INF-γ, IL-17	[137,159]	Ligand treatment: No effect	[155]	Ligand treatment: ↓severity	[101,105]
Colitis	PPARα^−/− mice: ↑severity	[137,159]	PPARβ/δ^−/− mice: ↑severity	[155]	PPARγ ^+/− mice: ↑severity	[101,105]
Carrageenan-induced	Ligand treatment: ↓severity	[135]	Ligand treatment: ↓severity	[160]	Ligand treatment: ↓severity	[161]
edema (acute inflammation)	Ligand treatment: ↓severity	[135]	Ligand treatment: ↓severity	[160]	Ligand treatment: ↓severity	[161]
Atherosclerosis	PPARα^−/− mice: ↓/↑lesions	[147, 148]	Ligand treatment: ↓lesions	[152]	Ligand treatment: ↓lesions (only in males)	[111,113]
Atherosclerosis	PPARα^−/− BMT: ↑lesions	[147, 148]	Ligand treatment: ↓lesions	[152]	PPARγ^−/− BMT: ↑lesions	[111,113]